contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


elicera-therapeutics-to-present-ipdated-carma-study-data-on-march-6-2026-at-the-10th-zurich-immuno-oncology-conference

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Elicera Therapeutics är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling inom immun-onkologi för cell- och genterapier för immunbaserad cancerbehandling. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster. Verksamheten bedrivs med störst närvaro inom Sverige. Elicera Therapeutics har sitt huvudkontor i Göteborg.

Elicera Therapeutics

Gothenburg, February 18, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform...

<div class="abstract">Gothenburg, February 18, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today announces that updated clinical data from the ongoing Phase I/IIa CARMA study with its lead CAR T-cell therapy candidate ELC-301 will be presented on March 6, 2026 at the&nbsp;10th Zurich Immuno-Oncology Conference 2026&nbsp;in Zürich, Switzerland.&nbsp;</div>The update will be presented by the Company's Chief Scientific Officer, Professor Magnus Essand, during an invited scientific presentation at the&nbsp;10th Zurich Immuno-Oncology Conference 2026&nbsp;in Zürich, Switzerland. The conference, held at Universitätsspital Zürich, brings together leading researchers and clinicians to discuss innovations in immuno-oncology.The presentation will include new data from&nbsp;two patients&nbsp;enrolled in&nbsp;cohort 3&nbsp;(the highest dose level to date) of the CARMA study, as well as longer-term follow-up data from patients treated in the previous two cohorts (dose levels 1 and 2). The CARMA study is evaluating the safety and preliminary efficacy of ELC-301, an autologous CD20-directed CAR T-cell therapy armed with the company's iTANK-technology, in patients with relapsed or refractory B-cell lymphoma. Previous updates from the first two cohorts (presented e.g. at the Karolinska ATMP Center inauguration in August 2025) showed promising signals, including complete metabolic responses in four of six treated patients, a favorable safety profile, and no dose-limiting toxicities observed to date. "We are pleased to share the next data update from the CARMA study in this prestigious scientific forum," said Professor Magnus Essand, Chief Scientific Officer of Elicera Therapeutics. "The presentation will highlight our efforts to optimize CAR T-cell performance through the iTANK platform, aiming for enhanced anti-tumor activity while minimizing toxicity - key challenges in solid and hematological malignancies." The company expects to issue a separate press release with key highlights from the presentation in connection with the event on March 6, 2026. For more information:&nbsp;<a href="https://www.usz.ch/en/event/10th-zurich-immuno-oncology-conference-2026/">https://www.usz.ch/en/event/10th-zurich-immuno-oncology-conference-2026/</a><div></div>

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference